Whereas the prevalence of IgE reactivity and clinical relevance of these candidate allergens should be further addressed in dedicated studies relying upon purified natural or properly folded recombinant molecules, we conclude that other allergens beyond the ones currently registered should be taken into account for the diagnosis and immunotherapy of short ragweed pollen allergy. This evidence concerns the gene IGHE and seasonal allergic rhinitis.